News Overview

The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals.

The partnership aligns with BharatPe’s mission to promote digital adoption and support local businesses, helping small food outlets reach a wider customer base.

The IPO will consist entirely of fresh equity share issuance, without any offer-for-sale (OFS) component.

The project will involve installing dynamic reactive compensation systems (STATCOMs) at two locations: Khavda Pooling Station 1 (KPS1) and Khavda Pooling Station 3 (KPS3) in Gujarat.

As of March 2024, the company had enabled approximately Rs 1.73 trillion in finance, benefiting more than 10 crore people in India.

The firm is a real estate developer specialising in high-end, sophisticated lifestyle residential complexes in Mumbai, Maharashtra.

The company may raise an additional ₹140 Crore by private placement, preferential allocation, or rights issue as part of a Pre-IPO placement.

Contract termination has a negative influence on turnover and proportionate profit due to the number of pending contracts to be executed.

FPIs infused $696 Million into Indian equities in a truncated week with FPI reporting only for 3 days

The transaction will be made using Security Receipts (SRs). The ARC will subscribe to 91.50% of the Security Receipts.